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We recently described two opposing states of transcriptional competency. One is termed ‘competent’
whereby a gene is capable of responding to trans-acting transcription factors of the cell, such that it is
active if appropriate transcriptional activators are present, though it can also be silent if activators are
absent or repressors are present. The other is termed ‘occluded’ whereby a gene is silenced by cis-acting,
chromatin-based mechanisms in a manner that blocks it from responding to trans-acting factors, such that
it is silent even when activators are present in the cellular milieu. We proposed that gene occlusion is a mech-
anism by which differentiated cells stably maintain their phenotypic identities. Here, we describe chromatin
analysis of occluded genes. We found that DNA methylation plays a causal role in maintaining occlusion for a
subset of occluded genes. We further examined a variety of other chromatin marks typically associated with
transcriptional silencing, including histone variants, covalent histone modiﬁcations and chromatin-associ-
ated proteins. Surprisingly, we found that although many of these marks are robustly linked to silent
genes (which include both occluded genes and genes that are competent but silent), none is linked speciﬁ-
cally to occluded genes. Although the observation does not rule out a possible causal role of these chromatin
marks in occlusion, it does suggest that these marks might be secondary effect rather than primary cause of
the silent state in many genes.
INTRODUCTION
A fundamental feature of multicellular organisms is the ability
of differentiated cell types to maintain their phenotypic iden-
tities over time irrespective of ﬂuctuations in the physiological
environment of the cells (1). How, at the molecular level, the
myriad cell types in an organism manage to stably preserve
their distinct identities is an important but little understood
question in biology. One attractive idea is that the identity
of a given cell type is safeguarded by the irreversible silencing
(or ‘occlusion’) of what can be referred to as lineage-
inappropriate genes—i.e. genes whose aberrant expression
would promote alternative lineages (2–6).
This idea received considerable support from our recent
study, which identiﬁed a state of stable gene silencing that
we termed the ‘occluded’ state (2). Speciﬁcally, we showed
that the transcriptional competency of a gene can exist in
one of two states: either competent or occluded. In the compe-
tent state, a gene is capable of responding to trans-acting tran-
scription factors of the cell such that it is active if appropriate
activators are present, though it can also be silent if activators
are absent or repressors are present. In the occluded state, in
contrast, a gene is no longer capable of responding to the
cell’s trans-acting milieu, presumably due to cis-acting chro-
matin marks, and remains silent even in the presence of acti-
vators. Experimentally, we used the ‘trans-complementation’
assay to identify occluded genes, which involves fusing two
disparate cell types and searching in fused cell for genes
silent in the genome of one fusion partner but active in the
other. The active orthologs of these genes attest to the pres-
ence of a trans-acting cellular milieu that is conducive to
the expression of the genes. Logically then, the silent ortho-
logs, which are bathed in the same milieu, must have been
blocked from the milieu’s action by the cis effect of their chro-
matin state—i.e. they are occluded.
Using trans complementation, we uncovered occluded
genes in a variety of mammalian cell types (2). Importantly,
we found that occluded genes in a given cell type tend to
include master regulators of alternative cell lineages. Further-
more, the occluded state is maintained during cell division and
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conditions. These results support the idea that the occlusion
of lineage-inappropriate genes could be a key mechanism by
which cell type identity is maintained.
An obvious next question to address is the biochemical
basis of gene occlusion. Numerous studies have linked
various chromatin marks—including DNA methylation,
histone variants, covalent histone modiﬁcations and the
binding of certain chromatin-associated proteins—to levels
of gene expression (7–15). These chromatin marks are thus
good starting points for investigating the biochemical basis
of occlusion. Here, we analyze a wide variety of chromatin
marks for their potential involvement in occlusion.
RESULTS
Analysis of DNA methylation using bisulﬁte sequencing
Our recent study identiﬁed occluded genes in a number of cell
types (2), including the human lung ﬁbroblasts MRC-5 (here-
after denoted hLF). In the study, we fused hLF with the mouse
skeletal muscle myoblasts C2C12 (hereafter mSMM) to search
for occluded genes in hLF. Given that this fusion was intended
to interrogate the occlusion status of genes in the hLF genome,
hLF was considered the responder in the fusion, whereas
mSMM was considered the reprogrammer. We identiﬁed 24
occluded and 10 transactivated genes in hLF via fusion with
mSMM (detailed descriptions of these genes are provided in
Supplementary Material, Table S1). Experimentally, occluded
and transactivated genes were deﬁned by gene expression pat-
terns in cells before and after fusion [see Table 1 and also refer
Lee et al. (2), for detailed deﬁnition of occluded versus trans-
activated genes]. Basically, both occluded genes and transac-
tivated genes are silent in the responder while active in the
reprogrammer prior to fusion. For occluded genes, this
expression pattern remains the same after fusion. For transac-
tivated genes, in contrast, their expression status in the respon-
der changes from silent to active upon fusion with the
reprogrammer. Transactivated genes are thus competent but
silent in the responder, and can turn on in response to the intro-
duction of transcriptional activators upon fusion.
To examine the potential role of DNA methylation in occlu-
sion, we ﬁrst performed a bioinformatic survey that identiﬁed
CpG islands in 18 of 24 occluded and 4 of 10 transactivated
genes in hLF (Fig. 1A). Occluded genes thus appear somewhat
enriched for CpG islands, though this is only marginally signiﬁ-
cant(P , 0.06byFisher’sexacttest).Wethenperformedexten-
sive bisulﬁte sequencing to analyze methylation patterns of a
subset of 10 genes, ﬁve of which were chosen from the 24
occluded genes, whereas the other ﬁve were selected from the
10 transactivated genes. Analysis was carried out on two cell
types: hLF and human skeletal muscle myoblasts (hSMM).
RT–PCR conﬁrmed that all 10 genes are expressed in hSMM
(data not shown), indicating their competent state in these cells.
Given that most of the genes are too big for bisulﬁte sequencing
in their entirety, we focused on putative cis-regulatory regions
identiﬁed by cross-species sequence conservation (see Materials
andMethods).Alsoincludedintheanalysisareregionssurround-
ing transcription start sites (TSS) and experimentally validated
enhancer elements irrespective of conservation.
Figure 1B and C shows representative results of the methyl-
ation analysis for one occluded gene (Myf5) and one transacti-
vated gene (Acta1). Results for the remaining eight genes are
presented in Supplementary Material, Fig. S1. In three of ﬁve
occluded genes (Myf5, Cacng1 and Rapsn), strong differential
methylation was observed between hLF and hSMM, with at
least a subset of the regions sampled having much higher levels
of methylation in hLF than hSMM. Of the remaining two
occluded genes, Myod1 showed mild differential methylation in
an enhancer far upstream of TSS, and Tnni2 did not show differ-
ential methylationbetween hLFandhSMM inanyof the regions
sampled. Incontrast tothe occluded genes, none of the transacti-
vatedgenesshoweddiscernabledifferentialmethylationbetween
hLFandhSMM.WenotethatforMyf5andCacng1,atleastsome
of the methylated regions in hLF fall within CpG islands.
AlthoughCpGislandsaregenerallyassumedtobeunmethylated,
there are clear exceptions such as many X-inactivated genes,
some imprinted genes and genes abnormally silent in cancer
cells (16–18). Furthermore, normal CpG methylation can
occasionally be found in non-imprinted, non X-inactivated
genes,ofteninatissue-speciﬁcmanner(19–21).Themethylation
within CpG islands of some occluded genes may therefore rep-
resent another example of such exceptions.
For the three occluded hLF genes that showed robust differ-
ential methylation between hLF and hSMM, the vicinity of
TSS is invariably a part of the differentially methylated
regions. We therefore used bisulﬁte sequencing to examine
the methylation status of TSS for the remaining 23 genes
(Ly75 is not included because it is technically refractory to
bisulﬁte sequencing). These remaining genes showed little or
no TSS differential methylation between hLF and hSMM,
regardless of whether they are occluded in hLF or not (Sup-
plementary Material, Fig. S2; data of TSS methylation analy-
sis also summarized in Fig. 1A). (Primer sequences of all
amplicons used in bisulﬁte sequencing are provided in Sup-
plementary Material, Table S2).
The above results demonstrate that for a subset of occluded
genes, the occluded state is characterized by increased methyl-
ation, especially around TSS. However, many occluded genes
do not show appreciable differential methylation in TSS
between occluded state in hLF and competent state in
hSMM, suggesting that either methylation is not involved in
conferring the occluded state to these genes or if it is involved,
it does so by acting in regions other than TSS. Data below are
in line with the latter possibility for at least some genes.
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2568 Human Molecular Genetics, 2009, Vol. 18, No. 14Figure 1. Bisulﬁte sequencing analysis of DNA methylation. (A) The 25 occluded and 10 transactivated genes in hLF that we uncovered previously (2). The
presence or absence of CpG island in each gene is indicated, along with whether transcription start site (TSS) is differentially methylated between hLF and
hSMM. (B) DNA methylation pattern of the occluded gene Myf5.( C) DNA methylation pattern of the transactivated gene Acta1. In the schema of gene structure,
exons are shown in solid bars with thick bars indicating coding regions and thin bars indicating untranslated regions. Bioinformatically identiﬁed CpG islands are
indicated. In the conservation graph, the height of peaks reﬂects the degree of cross-species conservation. Individual amplicons in bisulﬁte sequencing and their
corresponding genomic regions are indicated by brackets. Within each block of bisulﬁte sequencing data, columns correspond to CpG sites while rows corre-
spond to sequenced clones. Solid circles indicate methylated CpG; dots indicate unmethylated CpG.
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To further examine whether DNA methylation contributes
causally to the occluded state, we treated hLF with the
demethylating drug 5-aza-20-deoxycytidine (AdC) prior to
cell fusion. The treatment itself did not turn on the occluded
hLF genes. Upon fusion with mSMM, however, about half
of the occluded hLF genes showed variable levels of transac-
tivation (Fig. 2A). Yet, for the majority of these, the
expression levels of the hLF copies are notably lower than
that of the mSMM copies. This could reﬂect either hetero-
geneous response of cells to drug treatment or the fact that
for some of the occluded genes, demethylation only leads to
partial erasure of the occluded state. It is noteworthy that
AdC treatment can alter the occluded state of genes not
showing appreciable differential TSS methylation between
hLF and hSMM. It suggests that DNA methylation plays a
role in maintaining the occluded state of these genes, but it
does so by affecting regulatory regions outside of the immedi-
ate vicinity of TSS. These results, together with the bisulﬁte
sequencing data, argue that DNA methylation is a causal
factor contributing to the occlusion of at least some genes,
whereas there are likely other mechanisms that also contribute
to the occluded state.
Analysis of 20 chromatin marks by chromatin
immunoprecipitation
Besides DNA methylation, many chromatin marks have been
found to be over- or underrepresented at either silent loci of
the genome or regions believed to be heterochromatic (e.g.
the inactive X and the centromere) (12,13). We examined 20
such marks by chromatin immunoprecipitation (ChIP) fol-
lowed by PCR. These include seven histone modiﬁcations
(H3K9Ac, H3K4me3, H3K9me2, H3K9me3, H3K27me3,
H4K20me1 and H4K20me3), six histone variants (H1,
H2A.X, macroH2A, H2A.Z, H2A.Bbd and CENPA) and
seven chromatin-binding proteins (YY1 which is a key com-
ponent of Polycomb repressive complex 1, SUZ12 and
EZH2 which are key components of Polycomb repressive
complex 2, PARP-1, cohesin and HP1-a and HP1-g which
are mammalian homologs of Drosophila heterochromatin
protin-1). This list contains essentially all the major chromatin
marks that have been implicated in the regulation of gene
expression. We analyzed these marks for three classes of
genes in hLF: the 24 occluded and 10 transactivated genes
as depicted in Fig. 1A, and a set of 17 actively expressed
genes randomly selected from the microarray data and vali-
dated by RT–PCR. For all these genes, we focused on
the vicinity of TSS for chromatin analysis because it is the
predominant site of differential chromatin modiﬁcation
in association with gene activity (12,13,22). For a
few genes, validated enhancers were also included in the
analysis. (primer sequences of all amplicons used in
ChIP–PCR analysis are provided in Supplementary Material,
Table S3).
For the great majority of these marks, there are signiﬁcant
differences between silent genes (including both occluded and
transactivated genes) and expressed genes in a manner largely
consistent with the literature (Fig. 3A). Speciﬁcally, ﬁve
marks, H3K9Ac, H3K4me3, H2A.Z, PARP-1 and cohesin, are
enriched in expressed genes relative to silent genes, with the
enrichment being most notable for H3K4me3. In contrast, 11
marks, H3K9me2, H3K9me3, H3K27m3, H4K20me1,
H4K20me3, H1, H2A.X, macroH2A, CENPA, SUZ12 and
EZH2, show the opposite trend—i.e. they are enriched in
silent relative to expressed genes, with the most notable enrich-
ment seen in H3K9me2, H3K9me3, H3K27me3 and
H4K20me3. Four marks, H2A.Bbd, YY1, HP1-a and HP1-g,
did not show any signiﬁcant difference between silent and
expressed genes. In the comparison between occluded and
transactivated genes, however, none of the 20 marks showed a
signiﬁcant difference between the two categories of genes.
To produce a visually more intuitive representation of the
separation in chromatin signatures among the genes, we
used principal component analysis to reduce the
20-dimensional data from the 20 marks to two dimensions.
As expected, occluded genes and transactivated genes clus-
tered closely with each other, whereas expressed genes clus-
tered separately (Fig. 3B). These data indicate that, of the
chromatin marks surveyed, silent genes (including both
occluded and transactivated genes) and expressed genes are
highly distinct from each other, whereas occluded genes and
transactivated genes are rather similar.
Figure 2. Effect of AdC (A) and TSA (B) treatment on occluded genes in hLF. RT–PCR analysis of gene expression is performed on drug-treated hLF without
fusion and drug-treated hLF fused to mSMM. hLF, human lung ﬁbroblasts; mSMM, mouse skeletal muscle myoblasts.
2570 Human Molecular Genetics, 2009, Vol. 18, No. 14Figure 3. ChIP analysis of 20 chromatin marks in hLF. Genes targeted by the analysis can be divided into silent and expressed categories, with the silent category
further divided into occluded and transactivated groups. (A) PCR quantitation of ChIP for individual genes. Each bar represents a region interrogated by a PCR
amplicon. The height of each bar represents fold-enrichment, relative to input, of each gene. P-values are calculated from these data using the t-test and indicate
the statistical signiﬁcance that two groups of genes are distinct for the chromatin mark surveyed. Error bars are based on multiple replicates of the experiment.
NS, not signiﬁcant; hLF, human lung ﬁbroblasts. (B) Principal component analysis of ChIP data across the 20 chromatin marks.
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The above ChIP data failed to establish any difference in
histone acetylation between occluded and transactivated
states. To conﬁrm that histone acetylation is not causally
involved in occlusion, we treated hLF with the histone deace-
tylase inhibitor trichostatin A (TSA) prior to cell fusion. The
treatment essentially did not alter the occluded state of hLF
genes, with only Myod1 and Rcan2 showing very weak trans-
activation (Fig. 2B). This argues that, consistent with the ChIP
data, histone hypoacetylation is not causally linked to the
occluded state, even though histone hypoacetylation is
robustly associated with the lack of expression as demon-
strated by our data and many previous studies (9,12).
DISCUSSION
A variety of chromatin marks have been associated with the
silent state of genes. These marks, often referred to as ‘epige-
netic marks’ in the literature, include DNA methylation,
histone variants, covalent histone modiﬁcations and the
binding of chromatin-associated proteins, among others.
When a gene’s silent state is associated with certain chromatin
marks, it is often said to be undergoing ‘epigenetic silen-
cing’—a term that can sometimes invoke the sense that chro-
matin marks are the primary cause of silencing. In reality, it is
rarely known whether chromatin marks at a silent locus are
indeed the primary cause of silencing or just a secondary
effect (23). Consider the following rather plausible scenario.
When transcriptional activators of a gene are absent in the
cell, that gene assumes a set of chromatin marks by default.
But when transcriptional activators become available (say, as
a result of some signaling event), the gene’s silent state as
well as the associated chromatin marks is readily reverted.
In this case, chromatin marks associated with the silent state
of this gene are not the primary cause of silencing. Rather,
these chromatin marks are the secondary effect of the true
primary cause (i.e. the lack of transcriptional activators),
even if these makes play a role in the execution or enforce-
ment of silencing.
The above example shows that it is important to differen-
tiate between two situations of epigenetic silencing. In the
ﬁrst situation, cis-acting chromatin marks are the primary
cause of silencing such that the affected gene remains silent
irrespective of whether transcriptional activators for that
gene are present in the cell or not. In the second situation,
the trans-acting cellular milieu is the primary cause of silen-
cing (i.e. either the absence of transcriptional activators or
the presence of transcriptional repressors in the milieu),
whereas chromatin marks are just a secondary effect even if
they participate in executing or enforcing the silent state.
The ﬁrst situation is basically the occluded state, whereas
the second situation is the competent but silent state. These
two states can be distinguished by the trans-complementation
assay (2). Thus, the trans-complementation assay further
divides the silent portion of the genome into two classes: cis-
silenced (or occluded) genes for which cis-acting chromatin
marks are the primary cause of silencing and trans-silenced
genes for which the trans-acting cellular milieu is the
primary cause of silencing though the chromatin state of the
genes could also be affected as a secondary effect of silencing.
In this study, we attempted to probe which speciﬁc chroma-
tin marks contribute causally to occlusion. We uncovered evi-
dence that DNA methylation plays a causal role in maintaining
occlusion for a subset of occluded genes. However, it is much
less clear whether a variety of other chromatin marks, includ-
ing histone variants, covalent histone modiﬁcations and the
binding of chromatin-associated proteins, contribute causally
to occlusion. Indeed, although many of these marks are
linked robustly to silent genes, none shows detectable differ-
entiation between the two classes of silent genes: those that
are occluded and those that are competent but silent (i.e. trans-
activated genes) (Fig. 3). As yet, it is too early to draw any
ﬁrm conclusions from this study because it relies on a
limited number of genes and focuses on the vicinity of TSS.
Nevertheless, our data do raise the possibility that some of
the repressive marks (i.e. chromatin marks traditionally associ-
ated with gene silencing such as H3K9 methylation) might
only be a secondary effect rather than the primary cause of
silencing in many cases. This is not to say that these repressive
marks do not participate in the execution or enforcement of
silencing. For example, a repressive mark can result in more
closed (i.e. tightly packed) chromatin structure such that pro-
miscuous binding by RNA polymerase is inhibited, thus redu-
cing background expression. But such a repressive mark
cannot be considered as the primary cause of silencing, if it
can be readily erased by the introduction of transcriptional
activators into the cellular milieu. In this case, trans-acting
cellular milieu rather than the repressive mark is the true
primary cause of silencing, with the existence of the repressive
mark only secondary to the trans-acting milieu.
We thus suggest, as have others (23,24), that caution be
taken when discussing the role of chromatin marks in gene
silencing so as not to imply causality when that information
is not available. We further suggest that the ability to identify
occluded genes by the trans-complementation assay provides
a hitherto unavailable functional readout of chromatin state.
With this information, one can better investigate whether a
chromatin mark (or combination of marks) plays a causal
role or a secondary role in gene silencing.
MATERIALS AND METHODS
Cell culture
The hLF, MRC-5, were obtained from ATCC (CCL-171), and
so were the mSMM C2C12 (CRL-1772). hSMM were
obtained from Cambrex (CC-2580T25). These cells were cul-
tured under standard conditions following vendors’ instruc-
tions or as described previously (2,25,26).
DNA methylation analysis
Genomic regions targeted for bisulﬁte sequencing were chosen
on the basis of cross-species conservation as deﬁned by the
UCSC Genome Browser (Placental Mammal Conserved
Elements by 28-way Multiz Alignment) (27). DNA methyl-
ation analysis was performed by bisulﬁte mutagenesis sequen-
cing as described (28). Approximately 20 clones were
2572 Human Molecular Genetics, 2009, Vol. 18, No. 14sequenced for each region of interest and sequence ﬁles were
analyzed using BiQ Analyzer software (29). Primer sequences
of all amplicons used in bisulﬁte sequencing are provided in
Supplementary Material, Table S2. The analysis of Ly75’s
TSS was abandoned after six primer sets failed to amplify
the region.
Chromatin analysis using ChIP
ChIP was performed essentially as described previously (30),
with the following modiﬁcations. Samples were sonicated in
7 ml aliquots for nine cycles of 20 s at 33% power using a
Fisher Sonic Dismembrator Model 500 with a 0.5 in. ﬂat tip
horn. This amount of sonication yielded an average DNA frag-
ment size of 300 – 700 bp (data not shown). For immunopre-
cipitation from 7   10
6 cells, 40 ml of a 1:1 mixture of protein
A and protein G Dynabeads (Invitrogen) were coupled to
10 mg of antibody, and then incubated with sonicated chroma-
tin samples overnight. Immunoprecipitated chromatin was
eluted from beads in 150 ml elution buffer (50 mM Tris pH
8, 10 mM EDTA, 1% SDS), digested with proteinase K
(Roche) and DNA was puriﬁed using the GenCatch PCR
Cleanup Kit (Epoch Biolabs). Semi-quantitative PCR was per-
formed with template concentration and PCR cycle tailored to
each amplicon to obtain linear range ampliﬁcation. PCR pro-
ducts were resolved on agarose gel and visualized by ethidium
bromide staining. Densitometry analysis of background-
subtracted images of PCR bands was performed using the
Gel Analyzer module of ImageJ 1.37v (National Institutes of
Health, http://rsb.info.nih.gov/ij). Measured PCR band intensi-
ties were normalized to IP input controls. The value of each
data point was calculated as the average of at least three inde-
pendent replicates. Primer sequences of all amplicons used in
ChIP–PCR analysis are provided in Supplementary Material,
Table S3.
Antibodies used for ChIP were as follows with catalog
numbers in parentheses: H3K9Ac (ab4441), H3K4me3
(ab8580), H3K9me2 (ab1220), H3K9me3 (ab8898),
H3K27me3 (ab6002), H4K20me1 (ab9051), H4K20me3
(ab9053), H2A.X (ab11175), macroH2A.1 (ab37264), H2A.Z
(ab4174), H2A.Bbd (ab4175), cohesin (ab992) and HP1-g
(ab50365) were from Abcam; CENP-A (sc-22787), YY1
(sc-7341X) and PARP-1 (sc-53643) were from Santa Cruz
Biotechnology; H1 (05-457) and SUZ12 (04-046) were from
Millipore; HP1-a (2616) was from Cell Signaling Technology
and EZH2 (36-6300) was from Invitrogen.
For drug inhibition of DNA methylation, cells were plated
at 20–25% conﬂuence and treated with 10 mM AdC until the
cells had undergone two population doublings. Cell fusion
was then carried out and fused cells were incubated for four
more days without AdC. For drug inhibition of histone acety-
lation, cells were treated with 1 mM trichostatin A for 24 h
until just before fusion. For both AdC and trichostatin A treat-
ment, control cells not subject to fusion were exposed to the
same temporal course of drug treatment.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
ACKNOWLEDGEMENTS
We thank Nitzan Mekel-Bobrov for assistance in statistical
analysis of chromatin immunoprecipitation data. This work
was partly supported by National Institutes of Health grants
F32HL922792 (to J.G.), F32GM075503 (to G.E.S.) and
HL07605 (to E.C.B.).
Conﬂict of Interest statement. None declared.
FUNDING
Funding to pay the Open Access charge was provided by
Howard Hughes Medical Institute.
REFERENCES
1. Waddington, C.H. (1966) Principles of Development and Differentiation,
Macmillan, New York.
2. Lee, J.H., Bugarija, B., Millan, E.J., Walton, N.M., Gaetz, J., Fernandes,
C.J., Yu, W.H., Mekel-Bobrov, N., Vallender, T.W., Snyder, G.E. et al.
(2009) Systematic identiﬁcation of cis-silenced genes by trans
complementation. Hum. Mol. Genet., 18, 835–846.
3. Caplan, A.I. and Ordahl, C.P. (1978) Irreversible gene repression model
for control of development. Science, 201, 120–130.
4. Fisher, A.G. and Merkenschlager, M. (2002) Gene silencing, cell fate and
nuclear organisation. Curr. Opin. Genet. Dev., 12, 193–197.
5. Macaluso, M. and Giordano, A. (2004) How does DNA methylation mark
the fate of cells? Tumori, 90, 367–372.
6. Sparmann, A. and van Lohuizen, M. (2006) Polycomb silencers control
cell fate, development and cancer. Nat. Rev. Cancer, 6, 846–856.
7. Jaenisch, R. and Bird, A. (2003) Epigenetic regulation of gene expression:
how the genome integrates intrinsic and environmental signals. Nat.
Genet., 33 (suppl.), 245–254.
8. Goll,M.G.andBestor,T.H.(2005)Eukaryoticcytosinemethyltransferases.
Annu. Rev. Biochem., 74, 481–514.
9. Jenuwein, T. and Allis, C.D. (2001) Translating the histone code. Science,
293, 1074–1080.
10. Vermaak, D., Ahmad, K. and Henikoff, S. (2003) Maintenance of chromatin
states: an open-and-shut case. Curr. Opin. Cell Biol., 15, 266–274.
11. Goldberg, A.D., Allis, C.D. and Bernstein, E. (2007) Epigenetics: a
landscape takes shape. Cell, 128, 635–638.
12. Kouzarides, T. (2007) Chromatin modiﬁcations and their function. Cell,
128, 693–705.
13. Li, B., Carey, M. and Workman, J.L. (2007) The role of chromatin during
transcription. Cell, 128, 707–719.
14. Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B. and
Cavalli, G. (2007) Genome regulation by polycomb and trithorax proteins.
Cell, 128, 735–745.
15. Surani, M.A., Hayashi, K. and Hajkova, P. (2007) Genetic and epigenetic
regulators of pluripotency. Cell, 128, 747–762.
16. Heard, E., Clerc, P. and Avner, P. (1997) X-chromosome inactivation in
mammals. Annu. Rev. Genet., 31, 571–610.
17. Paulsen, M. and Ferguson-Smith, A.C. (2001) DNA methylation in
genomic imprinting, development, and disease. J. Pathol., 195, 97–110.
18. Esteller, M. (2007) Epigenetic gene silencing in cancer: the DNA
hypermethylome. Hum. Mol. Genet., 16 (Spec no. 1), R50–R59.
19. Eckhardt, F., Lewin, J., Cortese, R., Rakyan, V.K., Attwood, J., Burger,
M., Burton, J., Cox, T.V., Davies, R., Down, T.A. et al. (2006) DNA
methylation proﬁling of human chromosomes 6, 20 and 22. Nat. Genet.,
38, 1378–1385.
20. Shen, L., Kondo, Y., Guo, Y., Zhang, J., Zhang, L., Ahmed, S., Shu, J.,
Chen, X., Waterland, R.A. and Issa, J.P. (2007) Genome-wide proﬁling of
DNA methylation reveals a class of normally methylated CpG island
promoters. PLoS Genet., 3, 2023–2036.
21. Suzuki, M., Sato, S., Arai, Y., Shinohara, T., Tanaka, S., Greally, J.M.,
Hattori, N. and Shiota, K. (2007) A new class of tissue-speciﬁcally
methylated regions involving entire CpG islands in the mouse. Genes
Cells, 12, 1305–1314.
Human Molecular Genetics, 2009, Vol. 18, No. 14 257322. Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., Wang, Z.,
Wei, G., Chepelev, I. and Zhao, K. (2007) High-resolution proﬁling of
histone methylations in the human genome. Cell, 129, 823–837.
23. Ptashne, M. (2007) On the use of the word ‘epigenetic’. Curr. Biol., 17,
R233–R236.
24. Madhani, H.D., Francis, N.J., Kingston, R.E., Kornberg, R.D., Moazed,
D., Narlikar, G.J., Panning, B. and Struhl, K. (2008) Epigenomics: a
roadmap, but to where? Science, 322, 43–44.
25. Blau, H.M., Pavlath, G.K., Hardeman, E.C., Chiu, C.P., Silberstein, L.,
Webster, S.G., Miller, S.C. and Webster, C. (1985) Plasticity of the
differentiated state. Science, 230, 758–766.
26. Yaffe, D. and Saxel, O. (1977) Serial passaging and differentiation of
myogenic cells isolated from dystrophic mouse muscle. Nature, 270,
725–727.
27. Kuhn, R.M., Karolchik, D., Zweig, A.S., Trumbower, H., Thomas, D.J.,
Thakkapallayil, A., Sugnet, C.W., Stanke, M., Smith, K.E., Siepel, A.
et al. (2007) The UCSC genome browser database: update 2007. Nucleic
Acids Res., 35, D668–D673.
28. Vallender, T.W. and Lahn, B.T. (2006) Localized methylation in the key
regulator gene endothelin-1 is associated with cell type-speciﬁc
transcriptional silencing. FEBS Lett., 580, 4560–4566.
29. Bock, C., Reither, S., Mikeska, T., Paulsen, M., Walter, J. and Lengauer,
T. (2005) BiQ Analyzer: visualization and quality control for DNA
methylation data from bisulﬁte sequencing. Bioinformatics, 21,
4067–4068.
30. Li, Z., Van Calcar, S., Qu, C., Cavenee, W.K., Zhang, M.Q. and Ren, B.
(2003) A global transcriptional regulatory role for c-Myc in Burkitt’s
lymphoma cells. Proc. Natl Acad. Sci. USA, 100, 8164–8169.
2574 Human Molecular Genetics, 2009, Vol. 18, No. 14